The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
From through

  • Endocrine Care

    Ordu S, Gungor A, Yuksel H, Alemdar R, Ozhan H, Yazici M, Albayrak S

    The impact of pioglitazone therapy on glycemic control, blood pressure and inflammatory markers in patients with diabetes mellitus

    Acta Endo (Buc) 2010 6(1): 73-82 doi: 10.4183/aeb.2010.73

    Aim. The aim of our study was to investigate the effect of pioglitazone on glycemic and blood pressure control, on inflammation markers in diabetic patients.\r\nPatients and methods. Forty-nine diabetic patients who had been followed up as outpatients for 2.7 years and HbA1c was >7% were included in the study. The patients had never received thiazolidinedione therapy before. Clinical, metabolic variables, high-sensitive Creactive protein (hsCRP), homocysteine (HCY) and asymmetric dimethylarginine (ADMA) levels were measured. 30 mg pioglitazone were administered. The patients were followed up for six months and all the measurements were re-evaluated for comparison.\r\nResults. Body mass index (BMI) significantly increased after treatment. Fasting glucose, HbA1c and HsCRP were decreased. Insulin resistance was improved and HOMA-IR index was decreased after pioglitazone treatment [8 (?6.5) vs 4(?3.1); p<0.0001]. Pioglitazone improved lipid metabolism. Mean total cholesterol and LDL cholesterol levels were decreased and HDL cholesterol was increased after treatment. The decrease in triglyceride and homocysteine levels did not reach significance. Mean ADMA level did not change after therapy [0.62 (?0.39) vs 0.61 (?0.44); p=0.85].\r\nConclusion. Pioglitazone treatment in type 2 DM produced significant improvements in measures of glycemic control, plasma lipids, blood pressure and homocysteine levels. Pioglitazone had no influence on ADMA levels.
  • Case Report

    Ariturk Z, Islamoglu Y, Tekbas E, Cil H, Soydinc S, Yazici M

    An Unusual Presentation of Hyperthyroidism: Atrioventricular Complete Heart Block

    Acta Endo (Buc) 2011 7(3): 405-409 doi: 10.4183/aeb.2011.405

    Complete heart block associated with hyperthyroidism is infrequent, and the diagnosis of hyperthyroidism is usually not considered in the absence of tachycardia. A 55-year-old woman was admitted to our emergency clinic with dizziness and syncope attack. Her electrocardiogram showed complete heart block.\r\nHyperthyroidism had been diagnosed, and she had been treated with propylthiouracil as an anti-thyroid treatment 3 years ago, although she had not taken this drug during the last 2 months. Her thyroid function tests showed hyperthyroidism. Antithyroid treatment was started again. Her rhythm returned from complete atrioventricular block to normal sinus rhythm\r\non the seventh day of hospitalization.
  • General Endocrinology

    Yavuz DG, Temizkan S, Yazici D

    Serum Carboxymethyl-Lysine and Soluble Receptor for Advanced Glycation End Products in Hyperthyroid and Hypothyroid Patients

    Acta Endo (Buc) 2022 18(4): 436-441 doi: 10.4183/aeb.2022.436

    Purpose. The formation and accumulation of advanced glycation end products (AGEs) are enhanced with increased oxidative stress and inflammatory conditions. A hyperthyroid and hypothyroid state is associated with oxidative stress. This study aimed to evaluate skin AGE deposition, serum carboxymethyl-lysine (CML), and serum soluble receptor for AGEs (sRAGE) levels in hypothyroid and hyperthyroid patients. Methods. A total of 203 subjects were included in this cross-sectional study. After excluding diabetes mellitus, 103 newly diagnosed hypothyroid patients, 50 newly diagnosed hyperthyroid patients, and 50 control (euthyroid) subjects were enrolled. All tests were done before beginning the appropriate treatment. Accumulated AGEs in the skin collagen were measured by skin autofluorescence (SAF) using an AGE Reader. Results. SAF measurements were 1.82 ± 0.04, 1.80 ± 0.40, and 1.63 ± 0.30 arbitrary units for the hypothyroid, hyperthyroid, and euthyroid groups, respectively (p = 0.04). Serum CML levels were 8.2 ± 2.8, 10.2 ± 2.0, and 8.0 ± 3.3 ng/mL for the hypothyroid, hyperthyroid, and euthyroid groups, respectively (p = 0.01). sRAGE levels were similar between the groups. Serum thyroid-stimulating hormone and SAF measurements were positively correlated (r = 0.25, p = 0.02) in the hypothyroid group and negatively correlated in the hyperthyroid group (r = -0.36, p = 0.04). There was no correlation between CML and sRAGE levels. Conclusion. SAF measurements are increased in both hypo- and hyperthyroid normoglycemic patients. Serum CML levels are increased in hyperthyroid patients. Hypo and hyperthyroid states might be associated with acceleration of AGE accumulation and may have a long term effect on metabolic memory.